Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / FOLH1B

FOLH1B

Basics

Aliases:
This biomarker is also known as:
  • folate hydrolase pseudogene,
  • Putative folate hydrolase 1B,
  • Cell growth-inhibiting gene 26 protein,
  • Prostate-specific membrane antigen-like protein,
  • NAALADase,
  • putative N-acetylated-alpha-linked acidic dipeptidase,
  • PSMA-LIKE,
  • PSMAL,
  • folate hydrolase 1B,
  • FOLHP,
  • GCPIII,
  • PSM,
  • GCP3,
  • glutamate carboxypeptidase III,
  • FOLH2,
  • N-acetylated-alpha-linked-acidic dipeptidase,
  • Q9HBA9,
  • EC 3.4.-.-,
  • folate hydrolase 2,
  • putative folate hydrolase 1B,
  • prostate-specific membrane antigen-like protein,
  • cell growth-inhibiting gene 26 protein,

View in BioMuta

Description…

FOLH1B, or PSMAL, is a cytoplasmic protein. It has been found in the kidney and liver, and has not been detected in the prostate. GO annotations related to this gene include metallopeptidase activity and dipeptidase activity.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: FOLH1B

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Ovary

Attributes

Phase: One
QA State: Under Review

Overview

No additional ovarian data available.

Performance Comment

FOLH1B (PSMAL) was one of 50 tumor vasculature-associated genes with transmembrane or secreted protein products identified through expression profiling of ovarian cancer vascular cells. These 50 tumor vascular markers (TVMs) also had low or no expression in normal tissues. FOLH1B (PSMAL) was not in the group of 13 selected for further validation.

Prostate

Attributes

Phase: One
QA State: Under Review

Overview

Performance Comment

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.